



Please type a plus sign (+) inside this box →

+

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/981,876/Conf. # 8845
				Filing Date	October 19, 2001
				First Named Inventor	Steven M. Ruben
				Group Art Unit	1644
				Examiner Name	Haddad, Maher M.
Sheet	1	of	1	Attorney Docket Number	PZ001G67AP1D1

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
MT	AO	WO	90/14432		Genetics Institute, Inc.	11-29-1990	
MT	AP	WO	96/17925		Immunex Corporation	06-13-1996	
MT	AQ	WO	97/04097		Genetics Institute, Inc.	02-06-1997	
MT	AR	WO	97/07198		Genetics Institute, Inc.	02-27-1997	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
MT	AS	OCCHIODORO et al., "Human alpha-L-fucosidase: complete coding sequence from cDNA clones", Biochem. and Biophys. Res. Comm., 164(1):439-445 (1989)	
	AT	JACOBS et al., "Dendritic Cells: Antigen Presenting Cells of T and B Lymphocytes", J. of Cell. Biochem. Suppl. 0 (21A), page 19, abstr. No. C1-207 (1995)	
	AU	ROSNET et al., "Binding of Free Immunoglobulin Light Chains to VpreB3 Inhibits Their Maturation and Secretion in Chicken B Cells", J. Biol. Chem., 279(11):10228-10236 (Mar. 12, 2004)	
	AV	HESS et al., "Induction of pre-B cell proliferation after de novo synthesis of the pre-B cell receptor", PNAS, 98(4):1745-1750 (Feb. 13, 2001)	
	AW	RILEY et al., "CD20: a gene in search of a function", Semin. Oncol. 27(6 Suppl. 12):17-24 (Dec. 2000) (abstract only)	
MT	AX	O'NEAL, CHERYL, "Rituximab", Clin. J. Oncol. Nursing, 5(2):75-76 (2001)	

Examiner Signature	Maher Haddad	Date Considered	7/12/04
-----------------------	--------------	--------------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.